Clinical Trials
9 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT00003245 2018-11-15
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00718757 2013-08-28
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00003368 2013-03-21
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002759 2013-02-05
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003970 2013-01-24
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005626 2012-09-25
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00053144 2011-03-08
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Roswell Park Cancer Institute
Phase 1 Completed